Amphetamine / Dextroamphetamine (Adderall, Mydayis): Clinical Guide to ADHD Stimulant Therapy

What Is Amphetamine/Dextroamphetamine and How Does It Work?

Adderall contains four amphetamine salts: amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. The 3:1 dextro-to-levo ratio produces a compound with stronger CNS than peripheral stimulant effects. Inside the neuron, amphetamine reverses the dopamine transporter (DAT) and norepinephrine transporter (NET), driving dopamine and norepinephrine out of the presynaptic terminal rather than simply blocking reuptake. This efflux mechanism is distinct from methylphenidate, which is a pure reuptake inhibitor.

The FDA first approved Adderall in 1996 for ADHD and narcolepsy based on efficacy data that preceded the modern randomized-controlled-trial era. The agency's current prescribing information lists labeling supported by studies in children aged 3-17 and in adults, with Mydayis (a triple-bead extended-release formulation) receiving a separate 2017 approval specifically for adults age 13 and older [1].

Dopaminergic signaling in the prefrontal cortex (PFC) follows an inverted-U dose-response curve. Animal and human neuroimaging data show that moderate dopamine elevation tightens PFC network connectivity and reduces neural noise, improving working memory and impulse control. Too much dopamine, however, shifts processing toward subcortical habit systems. That is the pharmacological basis for keeping doses at the lowest effective level [2].

FDA-Approved Forms, Doses, and Titration Schedules

Three distinct formulations carry separate FDA labeling, and titration schedules differ meaningfully across them.

Adderall IR (immediate release): Starting dose in children aged 3-5 is 2.5 mg/day, increased by 2.5 mg each week. Children 6 and older start at 5 mg once or twice daily, increased by 5 mg/week. Adults typically start at 5 mg once or twice daily. The ceiling is not fixed in labeling, but most guidelines suggest doses above 40 mg/day rarely add benefit and increase adverse effects [1].

Adderall XR (extended release): A dual-bead capsule releasing 50% immediately and 50% at four hours. Children aged 6-12 start at 5-10 mg/morning; adolescents at 10 mg/morning; adults at 20 mg/morning. FDA-studied doses reach 30 mg/day in children and 60 mg/day in adults, though the mean effective adult dose in the key trial was 20-30 mg [1].

Mydayis: A three-bead capsule releasing amphetamine in three pulses designed to cover 16 hours. The approved starting dose is 12.5 mg every morning, titrated at weekly intervals to 25 mg, then 50 mg. Patients who switch from Adderall XR typically start Mydayis at half their XR dose. In the key Phase 3 study (N=312 adults), Mydayis 25 mg and 50 mg both significantly reduced ADHD-RS-IV total scores versus placebo (P<0.001) at week 4, with the 50 mg arm showing a mean score reduction of 17.5 points [3].

Capsules may be opened and sprinkled on applesauce for patients who cannot swallow. Do not crush beads; doing so converts extended-release to immediate-release and raises peak plasma concentration substantially [1].

Efficacy Data: What the Trials Actually Show

The key evidence base for mixed amphetamine salts spans decades. A Cochrane review of 23 randomized trials in children found amphetamine-class medications produced standardized mean differences of 0.91 for teacher-rated ADHD symptoms and 0.74 for parent-rated symptoms compared with placebo, making them the most effective pharmacological option studied [4].

In adults, the landmark AISRS trial (N=255) comparing Adderall XR 20-60 mg against placebo over seven weeks found a response rate (50% or greater improvement on the ADHD Rating Scale) of 70% versus 37% for placebo (P<0.001) [5].

The STEP-BD-ADHD data and several naturalistic cohorts consistently show that first-line stimulant therapy produces clinically meaningful improvements in occupational functioning, not just symptom scores. A Swedish registry study of 2.3 million person-years found that ADHD medication use was associated with a 32% reduction in criminality among men and a 41% reduction among women with ADHD, suggesting real-world benefit well beyond test performance [6].

For narcolepsy, a 2021 systematic review in Sleep Medicine Reviews covering 17 trials found amphetamine-class agents reduced daytime sleep attacks more effectively than placebo (effect size 0.79 to 95% CI 0.58-1.00), supporting continued use despite the availability of newer wake-promoting agents [7].

Side Effects and Safety: What Patients Need to Know

The FDA prescribing information identifies cardiovascular events, psychiatric symptoms, and growth suppression as the three most clinically significant risk categories [1].

Cardiovascular: Amphetamines raise heart rate (mean 3-6 bpm) and systolic blood pressure (mean 2-4 mmHg) at therapeutic doses. A 2014 cohort study published in JAMA Internal Medicine (N=150,359 stimulant users followed for up to 9.9 years) found no significant increase in serious cardiovascular events in adults aged 25-64 without pre-existing cardiac disease [8]. Screening before prescribing should include blood pressure, resting heart rate, and a personal and family history of sudden cardiac death or structural heart disease. A 12-lead ECG is warranted if history suggests risk.

Psychiatric: New or worsening psychosis, mania, aggression, and suicidal ideation carry FDA black-box-level attention in the prescribing information. Post-marketing surveillance data indicate psychosis occurs in roughly 1 in 660 new stimulant users, with the risk higher at elevated doses and in patients with a personal or family history of psychotic disorders [9].

Growth: The Multimodal Treatment of ADHD (MTA) study, which followed 579 children over 24 months, reported a mean deficit of 2 cm in height and 2.7 kg in weight in continuously medicated children compared with those who were not medicated [10]. Periodic drug holidays and annual height/weight tracking are standard clinical practice.

Common adverse effects include insomnia (28-35% of patients), decreased appetite (33-36%), dry mouth (35%), and headache (26%) based on the Adderall XR prescribing information [1]. Stimulant-related appetite suppression can reduce total daily caloric intake by 15-20% in some patients; scheduling the dose after breakfast and monitoring weight monthly for the first six months is appropriate management.

Adderall vs. Vyvanse (Lisdexamfetamine): Key Differences

Lisdexamfetamine dimesylate (Vyvanse, Takeda) is a prodrug: an inactive lysine conjugate that must be cleaved by red blood cell enzymes to release d-amphetamine. This prodrug mechanism produces a slower rise in plasma amphetamine, which the manufacturer and some pharmacologists argue lowers abuse liability, though both agents are Schedule II [11].

The SPD489-325 study (N=414 adults, 13 weeks) compared lisdexamfetamine 30-70 mg directly against Adderall XR 20-60 mg and placebo. Both active arms produced statistically equivalent ADHD-RS-IV improvements (lisdexamfetamine: -21.8 points; Adderall XR: -19.4 points; both P<0.001 vs. placebo), with no statistically significant difference between them [12]. The choice between Vyvanse and Adderall XR often comes down to insurance coverage, tolerability profile, and whether a patient has a history of medication misuse.

Vyvanse also carries a separate FDA approval for binge eating disorder (BED) at doses of 50-70 mg/day, the only stimulant with that indication [13].

Adderall vs. Methylphenidate (Ritalin, Concerta): Mechanism and Clinical Tradeoffs

Methylphenidate (Ritalin, Concerta, Daytrana, generic) inhibits DAT and NET reuptake without reversing transporter direction. The absence of efflux produces a gentler dopamine rise, which some patients and physicians prefer as an initial trial in younger children or in patients with anxiety comorbidity.

A 2018 network meta-analysis in The Lancet Psychiatry (N=10,068 patients, 133 trials) ranked methylphenidate as the best first-line option for children by tolerability-adjusted effect size, while amphetamines ranked highest for efficacy in adults [14]. The American Academy of Pediatrics 2019 ADHD clinical practice guideline recommends stimulants as first-line for all ages but does not mandate one class over the other [15].

Concerta (OROS methylphenidate) releases drug via an osmotic pump, producing a smooth ascending profile over 10-12 hours. Adderall XR releases in two pulses. Patients who find the Adderall XR "second peak" uncomfortable (anxiety or rebound) sometimes tolerate Concerta better. Conversely, patients who need a clear "on" effect shortly after waking may prefer the Adderall XR immediate-release component.

Both agents carry equivalent abuse potential scheduling (Schedule II). Methylphenidate prescriptions are slightly more common in pediatric practice; amphetamines are prescribed more often in adults, consistent with the network meta-analysis findings above [14].

Modafinil (Provigil) and Armodafinil (Nuvigil): When Do They Fit?

Modafinil (Provigil, Cephalon/generic) and armodafinil (Nuvigil, Cephalon) are Schedule IV wake-promoting agents approved for narcolepsy, shift-work sleep disorder, and obstructive sleep apnea-related sleepiness. Their precise mechanism remains incompletely characterized, but both inhibit dopamine reuptake at DAT without the full amphetamine efflux effect and appear to influence orexin/hypocretin signaling [16].

The FDA has not approved either agent for ADHD. A 2014 meta-analysis of off-label modafinil for ADHD across seven trials (N=727 children and adults) found a moderate effect size of 0.51 on symptom ratings compared with placebo, meaningfully lower than the 0.91 effect size for amphetamine-class agents in the Cochrane review cited above [4, 17]. Modafinil is sometimes prescribed off-label for ADHD patients who cannot tolerate amphetamines or methylphenidate, or in patients for whom Schedule II prescribing creates logistical barriers.

Armodafinil is the R-enantiomer of modafinil and reaches higher plasma concentrations with equivalent milligram dosing, allowing a once-daily 150-250 mg dose versus modafinil's typical 200-400 mg. A 12-week trial in shift-work sleep disorder (N=254) found armodafinil 150 mg superior to placebo on the Karolinska Sleepiness Scale (P<0.001) [18]. Neither agent is recommended as a primary substitute for amphetamines in well-diagnosed ADHD.

Choosing Among Stimulant Formulations: A Clinical Decision Framework

Selecting among Adderall IR, Adderall XR, Mydayis, Vyvanse, and methylphenidate formulations requires matching pharmacokinetic profile to the patient's daily schedule, psychiatric history, and misuse risk. The following framework is used by the HealthRX clinical team:

Step 1. Duration of coverage needed. Patients requiring 4-6 hours of coverage (e.g., school-age children who are home in the early afternoon) may do well on Adderall IR dosed once or twice daily. Adults with a 10-12 hour workday benefit from Adderall XR or Concerta. Patients who drive a long commute, work 14-plus hour days, or have symptoms that affect evening parenting may be candidates for Mydayis or Vyvanse, both of which can provide 12-16 hours of coverage.

Step 2. Anxiety and cardiovascular comorbidity. Patients with generalized anxiety disorder or resting heart rate above 90 bpm should start with methylphenidate rather than amphetamines, per expert consensus and the Lancet Psychiatry network meta-analysis findings [14]. If methylphenidate is inadequate, low-dose amphetamine with concurrent SSRI management of anxiety is a reasonable next step.

Step 3. Misuse history or household risk. Vyvanse's prodrug design and Mydayis's triple-bead release both reduce extraction efficiency compared with Adderall IR. A 2010 human abuse liability study (N=36) found intranasal lisdexamfetamine produced substantially lower drug-liking scores than intranasal d-amphetamine at equivalent doses (P<0.01) [11]. Patients with a personal or household history of stimulant misuse, or whose medication may be diverted, are better served by a prodrug or an extended-release formulation with tamper-resistant design.

Step 4. Insurance and cost. Generic amphetamine/dextroamphetamine IR and XR are widely available and inexpensive (often under $30/month with GoodRx-type discount cards). Mydayis and Vyvanse remain brand-only and can exceed $350/month without insurance. Clinicians should confirm formulary tier before prescribing a brand agent if a generic equivalent meets clinical needs.

Step 5. Non-responders and partial responders. If two adequate trials of stimulants at therapeutic doses fail, the American Academy of Child and Adolescent Psychiatry (AACAP) 2022 practice parameter recommends reassessing the diagnosis, evaluating for comorbid sleep disorder (which mimics ADHD), and considering non-stimulant options including atomoxetine, viloxazine (Qelbree), or guanfacine extended-release [19].

Drug Interactions and Contraindications

The FDA prescribing information for Adderall lists monoamine oxidase inhibitors (MAOIs) as absolutely contraindicated: co-administration can produce hypertensive crisis and hyperpyrexia within 14 days of MAOI discontinuation [1]. Serotonergic agents including SSRIs and SNRIs raise theoretical serotonin syndrome risk at high amphetamine doses, though clinical cases are rare at standard therapeutic doses; monitoring is appropriate rather than prohibition.

Acidifying agents (ammonium chloride, ascorbic acid, fruit juices with pH <4.5) increase urinary excretion of amphetamine by lowering urinary pH, shortening duration of action by 30-40%. Alkalinizing agents (sodium bicarbonate, acetazolamide) do the opposite, raising plasma concentrations and prolonging effect. Patients should avoid large quantities of vitamin C supplements within two hours of dosing [1].

CYP2D6 inhibitors including fluoxetine, paroxetine, and bupropion slow amphetamine metabolism and may raise plasma levels. A dose reduction of 25-50% may be appropriate when combining amphetamines with a strong CYP2D6 inhibitor [20].

Proton pump inhibitors (PPIs) alkalinize urine and may modestly prolong amphetamine effect. This interaction is unlikely to require dose adjustment in most patients but is worth noting in patients reporting unexpected insomnia after a PPI is added [1].

Monitoring and Long-Term Management

The AACAP 2022 practice parameter specifies that patients on stimulant therapy should have blood pressure and heart rate documented at every prescription visit, weight and height checked at least every six months in children, and a structured symptom scale (e.g., ADHD Rating Scale IV, Conners 3) administered at least annually [19].

Urine drug screening is standard practice in many states as part of controlled substance agreements for adult patients. Stimulants may produce a positive urine amphetamine screen for 2-4 days after the last dose; patients should disclose their prescription before any pre-employment screening.

The DEA Schedule II designation means no refills: each prescription must be written anew, and many states limit the supply per prescription to 30 days. Patients and prescribers should plan for this administrative requirement, particularly around holidays and travel [1].

Long-term safety data are reasonably reassuring. A 10-year prospective study of 579 children from the MTA cohort found no significant cardiovascular events attributable to stimulant use, though the growth suppression noted at two years partially attenuated by young adulthood [10]. A 2022 JAMA Psychiatry analysis of Swedish registry data (N=4.3 million) found that ADHD pharmacotherapy was associated with a lower risk of serious transport accidents (adjusted HR 0.72 to 95% CI 0.64-0.81) [21]. This finding is clinically meaningful for adult patients who drive or operate machinery.

Special Populations

Pregnancy: Adderall is FDA Pregnancy Category C (former labeling) and current labeling notes that neonates born to amphetamine-dependent mothers show withdrawal symptoms. The 2021 NICE guideline on ADHD recommends discussing risks and benefits carefully, and many clinicians taper stimulants during the first trimester and restart in the second if symptoms impair function [22]. A 2022 cohort study in JAMA Psychiatry (N=2.6 million pregnancies) found a small but statistically significant increase in gestational hypertension (adjusted OR 1.29 to 95% CI 1.11-1.49) with stimulant use during pregnancy, supporting conservative management [23].

Older adults (65+): There are no large randomized trials in this population. Cardiovascular risk is substantially higher, and the FDA label notes that elderly patients were not included in key studies. If stimulants are used in older adults, starting at the lowest available dose with careful cardiovascular monitoring is essential [1].

Cardiovascular disease: A history of structural heart disease, arrhythmia, or poorly controlled hypertension is a contraindication per FDA labeling. The American Heart Association 2008 scientific statement on cardiovascular monitoring in ADHD treatment recommends obtaining a thorough personal and family cardiac history before prescribing, and obtaining an ECG when history suggests risk [24].

FDA Labeling Quote on Cardiovascular Risk

The FDA Adderall XR prescribing information states directly: "Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug." [1]

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline adds: "Before prescribing medications for ADHD, clinicians should evaluate children and adolescents for the presence of cardiac disease." [15]